ESR1 and breast carcinoma: Despite these preclinical findings, clinical studies in ER+ breast cancer patients have demonstrated varied effects of glucocorticoid use on breast cancer patient survival, with modest effects when used as a single agent and no additive effect in combination with other drugs, including anti-oestrogens [154,155].